Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
25 Nov 2020
Historique:
received: 04 08 2020
accepted: 12 11 2020
entrez: 26 11 2020
pubmed: 27 11 2020
medline: 10 6 2021
Statut: epublish

Résumé

The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)? We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion. This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs. Clinicaltrials.gov NCT04081051 . Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.

Sections du résumé

BACKGROUND BACKGROUND
The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)?
METHODS METHODS
We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion.
DISCUSSION CONCLUSIONS
This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs.
TRIAL REGISTRATION BACKGROUND
Clinicaltrials.gov NCT04081051 . Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.

Identifiants

pubmed: 33239106
doi: 10.1186/s13063-020-04897-9
pii: 10.1186/s13063-020-04897-9
pmc: PMC7687811
doi:

Banques de données

ClinicalTrials.gov
['NCT04081051']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

974

Subventions

Organisme : Swiss Agency for Development and Cooperation, Global Health Division
ID : 810571721

Références

PLoS Negl Trop Dis. 2013 Jul 18;7(7):e2324
pubmed: 23875053
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
Zhonghua Gan Zang Bing Za Zhi. 2014 Oct;22(10):781-91
pubmed: 25558501
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Injury. 2010 Jul;41 Suppl 1:S3-6
pubmed: 20466367
PLoS One. 2014 Apr 22;9(4):e95868
pubmed: 24755844
J Pediatric Infect Dis Soc. 2016 Jun;5(2):190-205
pubmed: 27059657
Sci Rep. 2020 Feb 7;10(1):2080
pubmed: 32034188
J Glob Infect Dis. 2019 Jan-Mar;11(1):36-42
pubmed: 30814834
N Engl J Med. 2014 Feb 27;370(9):809-17
pubmed: 24571753
Clin Microbiol Infect. 2019 Jan;25(1):20-25
pubmed: 29625170
PLoS Negl Trop Dis. 2020 Apr 30;14(4):e0008268
pubmed: 32352959
Lancet Infect Dis. 2014 Mar;14(3):239-49
pubmed: 24332389
PLoS Negl Trop Dis. 2020 Jan 10;14(1):e0007927
pubmed: 31923174
Lancet Glob Health. 2013 Jul;1(1):e46-54
pubmed: 24748368

Auteurs

Olawale Salami (O)

Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland.

Philip Horgan (P)

Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Catrin E Moore (CE)

Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Abhishek Giri (A)

Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal.

Asadu Sserwanga (A)

Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala, Uganda.

Ashish Pathak (A)

RD Gardi Medical College, Ujjain, Madhya Pradesh, 456001, India.

Buddha Basnyat (B)

Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal.

Francois Kiemde (F)

Institut de Recherche en Sciences de la Santé Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso.

Frank Smithuis (F)

Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.

Freddy Kitutu (F)

Department of Pharmacy, School of Health Sciences, Makerere University, Kampala, Uganda.

Gajanan Phutke (G)

Jan Swasthya Sahyog, Ganiyari, India.

Halidou Tinto (H)

Institut de Recherche en Sciences de la Santé Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso.

Heidi Hopkins (H)

London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT, UK.

James Kapisi (J)

Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala, Uganda.

Myo Maung Maung Swe (MMM)

Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.

Neelam Taneja (N)

Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.

Rita Baiden (R)

Dodowa Health Research Centre, P.O. Box DD1, Dodowa, Ghana.

Shanta Dutta (S)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India.

Adelaide Compaore (A)

London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT, UK.

David Kaawa-Mafigiri (D)

School of Social Sciences, Makerere University, Kampala, Uganda.

Rashida Hussein (R)

Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.

Summita Udas Shakya (SU)

Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal.

Vida Kukula (V)

Dodowa Health Research Centre, P.O.Box DD1, Dodowa, Ghana.

Stefano Ongarello (S)

Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland.

Anjana Tomar (A)

FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001, India.

Sarabjit S Chadha (SS)

FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001, India.

Kamini Walia (K)

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, Ansari Nagar, New Delhi, 110029, India.

Cassandra Kelly-Cirino (C)

Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland.

Piero Olliaro (P)

Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland. piero.olliaro@finddx.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH